Drug Profile
Research programme: autoimmune disorder therapeutics - Kineta RLB
Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Kineta RLB
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for research development in Autoimmune-disorders in USA
- 15 Apr 2014 Early research in Autoimmune disorders in USA (unspecified route)
- 15 Apr 2014 Kineta and RLB Holdings form Kineta RLB for the development of therapeutics for the treatment of Autoimmune diseases